Multiple biochemical pathways were shown to be affected, such as cell cycle control, apoptosis, and angiogenesis.[42] In another recent publication, enzastaurin has been shown to be able to reverse acquired resistance to gefitinib, an EGFR small molecule inhibitor; while this study evaluated cell lines that are not NSCLC (colon cancer and prostate cancer), the mechanism observed may likely be observed in NSCLC.[43] The efficacy of combination enzastaurin and other cytotoxic agents in NSCLC might be dependent upon the schedule by which these drugs are delivered. Here, EGFR is linked to prostate carcinoma.